<DOC>
	<DOCNO>NCT01619280</DOCNO>
	<brief_summary>Acute lung injury ( ALI ) cause wide variety condition , always characterize hypoxia non-cardiogenic pulmonary edema . Current treatment ALI supportive treatment underlie cause . New therapy treat severe ALI show improve survival , limited financial logistical resource . The investigator propose investigate role inhale sodium nitroprusside ( iSNP ) ALI . Sodium nitroprusside ( SNP ) vasodilator . When inhaled , SNP may travel area lung participate gas exchange , cause blood vessel surround area enlarge . This may result increase blood vessel area lung , improve oxygenation . Currently , iSNP study adult population . Therefore , study intend find safety profile vary dos iSNP .</brief_summary>
	<brief_title>Safety Study Nebulized Sodium Nitroprusside Adult Acute Lung Injury</brief_title>
	<detailed_description>Acute lung injury ( ALI ) syndrome characterize acute hypoxemic respiratory failure bilateral pulmonary infiltrates attribute left atrial hypertension . ALI responsible significant mortality morbidity critically ill population . Novel rescue therapy use support oxygenation severe ALI include inhale nitric oxide high frequency oscillatory ventilation ; however , neither show reduce mortality limited logistical financial challenge . Inhaled sodium nitroprusside ( iSNP ) vasodilator cause local vasodilation pulmonary capillary surround functional alveolus , result improve oxygenation redistribute pulmonary blood flow area well ventilation-perfusion ratio . As iSNP administer low-cost nebulizer relatively inexpensive compare novel rescue therapy , modality may alternative therapy patient severe hypoxemia . Two pediatric study support use iSNP ALI ; however , iSNP study adult ALI population . To determine whether iSNP improve oxygenation adult ALI , maximum tolerable dose ( MTD ) must first determine . Our study aim determine MTD iSNP adult ALI open-label , non-randomized , single center , dose escalation study design , whereby subject receive iSNP thirty minute various physiologic variable record .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Lung Injury</mesh_term>
	<mesh_term>Nitroprusside</mesh_term>
	<criteria>1 . Age ≥ 18 2 . Negative βhCG woman child bear age ( age ≤ 50 ) 3 . Developed ALI within past 72 hour : PaO2/FiO2 &lt; 300 ; Bilateral infiltrate CXR ; No clinical evidence elevate left atrial pressure ie . Heart failure cause hypoxia bilateral infiltrates ; Recognized risk factor ALI : pneumonia , aspiration pneumonitis , acute pancreatitis , massive blood transfusion , sepsis 4 . FiO2 ≥ 0.5 5 . PEEP ≥ 8 cm H2O 6 . Invasive arterial blood pressure line 7 . Endotracheal intubation tracheostomy 8 . Conventional mechanical ventilation 9 . Mean Arterial Pressure ( MAP ) ≥ 65 mmHg without use vasopressor ( stable least 1 hour ) 10 . Arterial pH ≥ 7.15 1 . Chest tube active leak ( eg . bronchopulmonary fistula ) , 2 . Prone ventilation , inhale nitric oxide , inhaled prostacyclin , high frequency oscillatory ventilation , 3 . Lack consent , 4 . Untreated coarctation aorta , symptomatic severe/critical aortic stenosis document echocardiogram clinical history , 5 . Evidence increase intracranial pressure ( eg . dilate pupil , know intracranial trauma mass head CT ) , 6 . SpO2 &lt; 90 % , 7 . Contraindication SNP i.e . hypersensitivity , congenital optic atrophy , tobacco amblyopia , 8 . Active treatment IV transdermal nitroglycerin , 9 . G6PD deficiency 10 . CrCl &lt; 30 ml/min receive renal replacement therapy , 11 . Total bilirubin &gt; 68 µmol/L AST ALT level 2 time upper limit normal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Acute Lung Injury</keyword>
	<keyword>Acute Respiratory Distress Syndrome</keyword>
	<keyword>Sodium Nitroprusside</keyword>
	<keyword>adult</keyword>
	<keyword>Safety</keyword>
	<keyword>Dose Finding</keyword>
	<keyword>Phase 1</keyword>
	<keyword>3 + 3 design</keyword>
	<keyword>Nebulizers Vaporizers</keyword>
	<keyword>High-Frequency Ventilation</keyword>
	<keyword>nitric oxide</keyword>
	<keyword>lung injury</keyword>
	<keyword>Pulmonary Gas Exchange</keyword>
	<keyword>Pulmonary Alveoli</keyword>
</DOC>